logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 

Equities – Your destination to connect with the growth investment community.

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GSK
Jag Shur
27 Apr 15 13:39:14
Glaxo's malaria vaccine candidate reduced cases in young children 36% in study $GSK http://t.co/4LSrVCL4lT
Charles Zinnel
27 Apr 15 13:26:53
$AEZS rallying 12% after hours on positive Phase III news! http://t.co/e7JB6X2pBX $pfe $jnj $gsk $mrk $ctic $heb #money #fed #stocks
Charles Zinnel
27 Apr 15 13:23:04
$AEZS rallying 16% after hours on positive Phase III news! http://t.co/e7JB6X2pBX $pfe $jnj $gsk $mrk $ctic $heb #money #fed #stocks
Usman zahid
27 Apr 15 13:10:24
RT @Bidnessetc: Pfizer Rumored To Be Eyeing British Giant GlaxoSmithKline plc (ADR) - http://t.co/HL0QAUQDLB $PFE $GSK $PFE $GSK http://t.c…
Robin O
27 Apr 15 12:12:04
RT @pharmalot: Pfizer & Glaxo are slammed by Doctors Without Borders over #vaccine pricing.. read the report.. http://t.co/JqafjX4S9C #phar…
PolgarStocks
27 Apr 15 11:52:08
$SINA stock Shares Click Here: http://t.co/Vd9DT9RPPu Also See: $ANGI $GSK $SBGL $SAM #stockmarket #tradeideas ~
Bidness Etc
27 Apr 15 11:37:31
Pfizer Rumored To Be Eyeing British Giant GlaxoSmithKline plc (ADR) - http://t.co/HL0QAUQDLB $PFE $GSK $PFE $GSK http://t.co/fpcm4xtD4c
jim50
27 Apr 15 11:34:35
GSK Glaxosmithkline Plc Gapped Up: +0.46 Last: 47.26 Volume: 3,505,044 http://t.co/YMRbUDLdHh $GSK #tradeideas ~
Warren of Wall St
27 Apr 15 10:57:05
$GSK Established income payer with good future prospects, but with questionable financial health. http://t.co/VO3HBoXOtU
biotech 2050
27 Apr 15 10:31:07
$OMED potential milestones $GSK $CELG #BAYER #blockbusters http://t.co/Jbf7A1h6gF
Ashley Armstrong
27 Apr 15 10:02:55
RT @gjlevett: Pfizer for GlaxoSmithKline... When this - http://t.co/js5f8srRHi turns into this - http://t.co/dTWbF8QPT8 $GSK $PFE
Market Parse
27 Apr 15 09:19:10
@WebbJulieAnne Since your tweet was sent $GSK has risen 1.615%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
ChuckSometimes
27 Apr 15 08:58:18
RT @HillaryGoode: MaximumPenny New Pick! The BIGGEST MJ Play of 2015 is $UBQU ! See link: http://t.co/GHbsfvaZqp $THCZ $NGCG � $LFAP $GSK …
John Turner
27 Apr 15 08:35:54
$GSK Stock to Follow: GlaxoSmithKline PLC (ADR) (NYSE:GSK) http://t.co/QevrxRnRVA
Clair Voight
27 Apr 15 08:35:52
$GSK Pfizer Inc. (PFE) Rumored To Be Eyeing British Giant GlaxoSmithKline plc (ADR) http://t.co/8FpmRXlz0G
PolgarStocks
27 Apr 15 08:33:49
$RLH stock Dividend Click Here: http://t.co/VPGMkH4GSG Also See: $GSK $EHIC $INBK $PSID #stockmarket #tradeideas ~
Your WallSt Reporter
27 Apr 15 08:25:43
MaximumPenny New Pick! The BIGGEST MJ Play of 2015 is $UBQU ! See link: http://t.co/GHbsfvaZqp $THCZ $NGCG � $LFAP $GSK $ROX
Helen Ong
27 Apr 15 08:17:56
$GSK readies "bubble boy" drug as big pharma bets on gene therapy http://t.co/MYIhiDctLf
Charles Zinnel
27 Apr 15 07:59:56
#silver spot experiencing massive short squeeze! $slv $pfe $jnj $gsk $mrk $ctic $heb #money #fed #stocks
Market Int Center
27 Apr 15 07:54:05
GlaxoSmithKline PLC $GSK Showing Resistance Near $47.18 ( http://t.co/FMbH4G6j2E )
Robert Stanislaro
27 Apr 15 07:48:51
RT @NatalieGrover: #GSK readies "bubble boy" drug as big pharma bets on gene therapy http://t.co/LHn5bIctoX via @Reuters $GSK #genetherapy
pahado ki mockingjay
27 Apr 15 07:45:13
RT @MarketParse: @jyochamoli Since your tweet was sent $GSK has risen 2.110%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
Natalie Grover
27 Apr 15 07:44:34
#GSK readies "bubble boy" drug as big pharma bets on gene therapy http://t.co/LHn5bIctoX via @Reuters $GSK #genetherapy
Market Realist
27 Apr 15 07:41:45
Why Investors Should Keep an Eye on the May 7 UK Elections $EWU $LYG $BP $GSK http://t.co/3MEVcBET3s
MAISA
27 Apr 15 07:33:52
$GSK first company to file for marketing approval for a gene therapy when it submits its ADA Severe Combined Immune Deficiency in Europe
Stoxline Investing
27 Apr 15 07:33:29
$GSK Volume is good Would like to see a break above $48.81. http://t.co/PCMB3gWTdq
Market Parse
27 Apr 15 07:32:51
@Gupta_Calling Since your tweet was sent $GSK has risen 2.110%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
Market Parse
27 Apr 15 07:32:51
@HillaryGoode Since your tweet was sent $GSK has risen 2.110%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
Market Parse
27 Apr 15 07:32:51
@jyochamoli Since your tweet was sent $GSK has risen 2.110%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
Market Parse
27 Apr 15 07:32:51
@PharmaPundit Since your tweet was sent $GSK has risen 2.110%. See your featured tweet on Market Parse http://t.co/YHInvBkJcO
Anthony
27 Apr 15 07:32:10
RT @WallStJesus: $GSK BULL FLOW, JUNE 49 C
Anthony
27 Apr 15 07:30:51
RT @OptionsHawk: $GSK as $PFE Next Target is interesting, we took the May $46 calls $1.15 that were hot Friday, good start http://t.co/IJ0C…
Scott Spencer
27 Apr 15 07:23:10
$AGEN +11% $7.95 new 52-wk high on $GSK Ph3 study final result with Agenus' QS-21 showing significant reduction against malaria in children.
Douglas Allan
27 Apr 15 07:18:41
$GSK readies "bubble boy" drug as big pharma bets on gene therapy http://t.co/QfOxTOt7Fl
Yuppy
27 Apr 15 07:17:26
RT @OptionsHawk: $GSK as $PFE Next Target is interesting, we took the May $46 calls $1.15 that were hot Friday, good start http://t.co/IJ0C…
Matthew Warmuth
27 Apr 15 06:57:40
RT @MaisaCorp: $SNTA new CEO, has led licensing and merger-and-acquisition transactions valued at more than $8B with partners $GSK $AMGN $P…
Mother of Sin
27 Apr 15 06:57:04
Took some + .30 on $JNJ calls Daytrade $GSK 49 JUN CALLS for +.10
MomoprtnrsLLC
27 Apr 15 06:57:02
$gsk big call buyers again right through resistance
Becky Hiu
27 Apr 15 06:56:50
$GSK - deal no deal deal no deal? Watch this one.
Reggie Noble
27 Apr 15 06:55:39
$GSK cashed out...quick 50% profit...Probably this keeps bouncing but learned to take the money and run..on to the next trade..
Open Outcrier
27 Apr 15 06:53:00
$GSK May 46 Call buyer +1k for $1.85
dougheuring
27 Apr 15 06:44:59
RT @markflowchatter: $PFE for $GSK speculation - http://t.co/FsF1PsYviF
Stock Trade Alerts
27 Apr 15 06:40:55
RT @OpenOutcrier: $GSK Jun 49 Call buyer +2k for $0.65 (Had pre-market chatter with $PFE rumored)
JE$US
27 Apr 15 06:35:55
$GSK BULL FLOW, JUNE 49 C
Open Outcrier
27 Apr 15 06:35:28
$GSK Jun 49 Call buyer +2k for $0.65 (Had pre-market chatter with $PFE rumored)
Lucabonti77
27 Apr 15 06:33:37
RT @BioStocks: Telegraph article: $GSK takeover target for $PFE http://t.co/zBAFyPQUTJ
Greg Levett
27 Apr 15 06:14:14
Pfizer for GlaxoSmithKline... When this - http://t.co/js5f8srRHi turns into this - http://t.co/dTWbF8QPT8 $GSK $PFE
biotech 2050
27 Apr 15 06:04:33
Wonder which company is $CELG's next target whilst $CELG might itself be a target by $BMY $NVS $PFE $RHHBY $GSK https://t.co/WiNIS4Vru2
biotech 2050
27 Apr 15 06:00:44
RT @BioStocks: Telegraph article: $GSK takeover target for $PFE http://t.co/zBAFyPQUTJ
Daniel Ward
27 Apr 15 05:59:25
RT @BioStocks: Telegraph article: $GSK takeover target for $PFE http://t.co/zBAFyPQUTJ
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.